163 related articles for article (PubMed ID: 20728981)
1. Serous and mucinous borderline ovarian tumors: are there real differences between these two entities?
Benito V; Lubrano A; Arencibia O; Medina N; Álvarez Eva E; Andújar M; Falcón Juan M; Falcón O
Eur J Obstet Gynecol Reprod Biol; 2010 Dec; 153(2):188-92. PubMed ID: 20728981
[TBL] [Abstract][Full Text] [Related]
2. [Clinical and pathological features of borderline ovarian tumors].
Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathologic features of 234 cases with borderline ovarian tumors].
Ren J; Lou JY; Liu H; Wang P; Zhang JW; Yang KX; Wang HJ; Qie MR; Peng ZL
Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):116-20. PubMed ID: 19570422
[TBL] [Abstract][Full Text] [Related]
4. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
5. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors?
Cho YH; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Nam JH
Gynecol Oncol; 2006 Dec; 103(3):878-82. PubMed ID: 16859736
[TBL] [Abstract][Full Text] [Related]
6. [Borderline ovarian tumors].
Ivanov S
Akush Ginekol (Sofiia); 2002; 42(1):23-5. PubMed ID: 11935694
[TBL] [Abstract][Full Text] [Related]
7. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
[TBL] [Abstract][Full Text] [Related]
8. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
9. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S
Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214
[TBL] [Abstract][Full Text] [Related]
10. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
11. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
[TBL] [Abstract][Full Text] [Related]
12. Ovarian serous borderline tumors with invasive peritoneal implants.
Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
[TBL] [Abstract][Full Text] [Related]
13. [Profiling of serum tumor markers in patients with epithelial ovarian carcinoma].
Dong L; Li XP; Cui H; Wang JL; Wei LH; Zhao Y; Wang SJ; Wang Y; Sun XL; Liang XD; Li Y
Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):121-5. PubMed ID: 19570423
[TBL] [Abstract][Full Text] [Related]
14. Current issues in the pathology of ovarian cancer.
Rabban JT; Bell DA
J Reprod Med; 2005 Jun; 50(6):467-74. PubMed ID: 16050571
[TBL] [Abstract][Full Text] [Related]
15. [Accuracy of frozen section in diagnosis of ovarian tumors].
Zhang GN
Zhonghua Fu Chan Ke Za Zhi; 1993 Oct; 28(10):601-3, 635. PubMed ID: 8112130
[TBL] [Abstract][Full Text] [Related]
16. [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
Hu CJ; Zhang F; Chen YJ; Sun XM; Zheng JF
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):520-3. PubMed ID: 19950700
[TBL] [Abstract][Full Text] [Related]
17. TFF3 Expression as Stratification Marker in Borderline Epithelial Tumors of the Ovary.
El-Balat A; Schmeil I; Karn T; Becker S; Sänger N; Holtrich U; Arsenic R
Pathol Oncol Res; 2018 Apr; 24(2):277-282. PubMed ID: 28470574
[TBL] [Abstract][Full Text] [Related]
18. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
19. Is MRI a useful tool to distinguish between serous and mucinous borderline ovarian tumours?
Bazot M; Haouy D; Daraï E; Cortez A; Dechoux-Vodovar S; Thomassin-Naggara I
Clin Radiol; 2013 Jan; 68(1):e1-8. PubMed ID: 23044365
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of two groups of patients with serous and mucinous types of borderline ovarian tumors].
Makarewicz H; Emerich J; Olszewski J
Ginekol Pol; 2003 Jan; 74(1):24-31. PubMed ID: 12715434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]